TOKYO & SAN FRANCISCO--(BUSINESS WIRE)--Astellas Pharma Inc. (TSE: 4503) and Medivation Inc. (NASDAQ: MDVN) today announced the online publication in the New England Journal of Medicine of the results from the Phase 3 PREVAIL trial. The PREVAIL trial is an international, randomised, double-blind, placebo-controlled clinical study of enzalutamide (XTANDITM) in men with metastatic castration-resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy and in whom chemotherapy is not yet clinically indicated. Enzalutamide is currently approved in Europe for the treatment of adult men with mCRPC whose disease has progressed on or after docetaxel chemotherapy.i The paper, “Benefit of Enzalutamide in Men with Chemotherapy-Naïve Metastatic Prostate Cancer,” appears in the June 1 online issue.
Help employers find you! Check out all the jobs and post your resume.
